KPTI News and Press, Karyopharm Therapeutics Inc. From 12/02/21

Karyopharm Therapeutics (NASDAQ:KPTI) announces the completion of patient recruitment in Phase 3 SIENDO study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer. Top-line data from this event-driv...

Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer - Top-Line Study Results Expected by End of 2021 or Early 2022 - PR Newswire NEWTON, Mass. , Dec. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics...

Karyopharm to Host Virtual Investor Day on December 8, 2021 PR Newswire NEWTON, Mass. , Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will ...

During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...

Karyopharm to Participate at Jefferies London Healthcare Conference PR Newswire NEWTON, Mass. , Nov. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q3 - Results - Earnings Call Presentation

Should Investors Be Buying These Top Health Care Stocks Today? Health care stocks , among other things, could be in focus in the stock market today . Namely, this would be thanks to the Biden administration’s latest COVID-19 vaccine mandate. In detail, U.S. employers ...

Karyopharm Therapeutics (KPTI +0.4%) is rising on new data from a phase 2 study selinexor in patients with myelofibrosis (MF) who were resistant or intolerant to JAK inhibitors. MF is a type of bone marrow cancer that disrupts the body's ability to produce normal blood cells. The main go...

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition -- 33% of Patients Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Response, Defined ...

Image source: The Motley Fool. Karyopharm Therapeutics inc (NASDAQ: KPTI) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics inc (KPTI) Q3 2021 Earnings Call Transcr...